

# Development of osteoarthritis drug with a novel mechanism of inflammasome blockade

Innovo Therapeutics, Inc.



OTHERS	Preclinical
Product Type	Intra-articular (IA) injection
Indication	Pain killer for osteoarthritis, with potential DMOAD (disease-modifying osteoarthritis drug)
Target	Inflammasome (inhibition)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Caspase-1 inhibition (inflammation blockade)</li> <li>• Caspase 3,8 &amp; 9 inhibition (Disease Modifying)</li> </ul>
Competitiveness	<ol style="list-style-type: none"> <li>1. Once a month dosing</li> <li>2. Novel mechanism of action</li> <li>3. Superior pain control to conventional therapy</li> <li>4. Minimal systemic exposure expected, compared to oral administration</li> <li>5. Potential DMOAD based on caspase 3,8 &amp; 9 inhibition</li> </ol>
Development Stage	Preclinical
Route of Administration	Intra-articular (IA) injection